Trending Topics in Gastroenterology | GastroAGI

A Steroid-Sparing Breakthrough(Obexelimab) for IgG4-Related Disease: NEJM | June 2026

Introduction: IgG4-related disease (IgG4-RD) is a chronic fibroinflammatory disorder that can affect virtually any organ. Although glucocorticoids remain the mainstay of treatment, relapse is common after tapering, and long-term steroid toxicity remains a major concern. The INDIGO trial evaluated obexelimab, a novel B-cell modulator, as a steroid-sparing therapy. Why was this study needed? • Relapse is common after glucocorticoid withdrawal in IgG4-RD. • Long-term corticosteroid therapy is associated with substantial toxicity. • Effective steroid-sparing therapies are limited. • Conventional B-cell depletion has safety and relapse concerns. • Novel targeted therapies are needed to maintain durable remission. Results: • Obexelimab significantly reduced disease flares, prolonging flare-free survival compared with placebo over 52 weeks. • Patients receiving obexelimab achieved higher complete remission rates while requiring substantially less rescue glucocorticoid therapy. • Obexelimab was well tolerated, with fewer serious adverse events than placebo despite mild increases in arthralgia, hypersensitivity, and diarrhea. Clinical Impact: The INDIGO trial establishes obexelimab as the first phase III biologic to demonstrate robust steroid-sparing efficacy in IgG4-related disease. Unlike conventional B-cell-depleting therapies, obexelimab modulates B-cell activity without depleting B cells, offering a novel therapeutic approach with the potential to reduce long-term corticosteroid exposure. Bottom Line: Obexelimab represents a major therapeutic advance for IgG4-related disease. It significantly reduces disease flares, increases sustained remission, and minimizes glucocorticoid exposure, making it a promising new targeted treatment for this chronic multisystem disorder.

HBV Reactivation During Immunosuppressive Therapy: Alimentary Pharmacology & Therapeutics | July 2026

Introduction: Hepatitis B virus (HBV) reactivation remains a potentially serious complication of immunosuppressive and anticancer therapies. While current guidelines classify patients into high-, moderate-, and low-risk categories, this editorial discusses new real-world evidence suggesting that HBV reactivation risk is more dynamic than previously appreciated. Key Takeaways: • Current HBV risk stratification remains broadly valid, with anti-CD20 therapies continuing to carry the highest risk of HBV reactivation. • Clinically meaningful HBV reactivation can still occur in patients considered "low risk," particularly those receiving low-dose or short-term corticosteroids. • HBV risk is dynamic rather than binary, influenced by cumulative immunosuppression, combination therapies, host factors, and monitoring intensity. • Tyrosine kinase inhibitors, anthracyclines, and several targeted therapies also demonstrated clinically relevant HBV reactivation risk. • Even with regular HBV DNA monitoring, some patients progressed to hepatitis, highlighting the limitations of surveillance alone. • The findings renew the debate over HBV DNA monitoring versus universal antiviral prophylaxis, especially in patients receiving prolonged or multidrug immunosuppressive therapy. • Treatment decisions should consider the overall immunosuppressive burden rather than relying solely on individual drug-risk categories. Clinical Impact: This editorial reinforces current guideline recommendations while emphasizing that "low risk" should never be interpreted as "no risk." Careful HBV screening, individualized risk assessment, close monitoring, and timely antiviral prophylaxis remain essential for patients receiving immunosuppressive therapy. Bottom Line: HBV reactivation risk exists across the entire spectrum of immunosuppressive therapy. Rather than depending solely on static drug-based categories, clinicians should adopt a dynamic, patient-centered approach that accounts for cumulative immunosuppression and individual risk factors.

Advancing Liver Health in a Shifting Global Landscape: Nat Re Gastro & Hepatol | July 2026

Introduction: Liver disease is entering a new era. While steatotic liver disease (SLD) is rapidly becoming one of the world's leading non-communicable diseases, progress toward viral hepatitis elimination has slowed. This editorial highlights the urgent need for coordinated global strategies to improve liver health and reduce inequities in prevention, diagnosis, and care. Key Takeaways: • The World Health Assembly has officially recognized steatotic liver disease (SLD) as a major non-communicable disease, marking a historic milestone for global liver health. • MASLD affects an estimated 1.3 billion people worldwide, with the global burden expected to increase substantially by 2050. • MetALD (Metabolic and Alcohol-Related Liver Disease) is increasingly recognized as an important contributor to liver-related morbidity, particularly in Europe. • Despite progress, viral hepatitis remains a major global health challenge, and the WHO 2030 elimination targets are unlikely to be achieved without stronger implementation. • Encouragingly, new HBV infections and hepatitis C-related deaths continue to decline, reflecting the impact of vaccination and antiviral therapies. • Healthcare inequities, limited access to prevention and treatment, and armed conflicts remain major barriers to improving liver health worldwide. • Integrating liver disease into national non-communicable disease (NCD) strategies is essential to reduce liver-related mortality, hepatocellular carcinoma, and cardiometabolic complications. Clinical Impact: This editorial emphasizes that liver health should no longer be viewed in isolation. Prevention of MASLD, alcohol-related liver disease, viral hepatitis, and liver cancer requires coordinated public health policies, equitable access to care, and integration into broader cardiometabolic and NCD programs. Bottom Line: Global liver health is at a turning point. While recognition of steatotic liver disease as a major NCD represents a landmark achievement, accelerating prevention, expanding access to care, and reducing global health inequities will be critical to lowering the future burden of liver disease.

ML Predicts Response to TPE in Pediatric ALF: JCEH | July 2026

Introduction: Therapeutic plasma exchange (TPE) is increasingly used in pediatric acute liver failure (ALF), but it artificially lowers bilirubin and INR, making it difficult to determine whether a child is truly improving or requires urgent liver transplantation. This study developed machine learning (ML) models to predict response to TPE and support real-time clinical decision-making. Why was this study needed? • TPE alters conventional prognostic markers, complicating transplant decisions. • Reliable early predictors of TPE response are lacking. • Delayed recognition of treatment failure may adversely affect survival. • Machine learning may improve individualized risk prediction. • A real-time clinical decision support tool could enhance patient management. Results: • Machine learning models accurately predicted response to TPE, with the best performance 12–18 hours after the first TPE session, allowing early identification of responders and non-responders. • Logistic Regression, Support Vector Machine (SVM), and XGBoost showed the highest predictive performance, consistently outperforming other ML models. • These validated models were integrated into a web-based clinical decision support tool, enabling real-time prediction of TPE response to assist liver transplant decision-making. Clinical Impact: This study demonstrates that artificial intelligence can support critical decision-making in pediatric acute liver failure by identifying children unlikely to respond to TPE at an early stage. Such tools may help optimize transplant timing while avoiding unnecessary delays in life-saving treatment. Bottom Line: Machine learning can accurately predict response to therapeutic plasma exchange in pediatric acute liver failure. A simple web-based prediction tool may assist clinicians in determining which children are likely to recover with TPE and which may require urgent liver transplantation.

Alcohol Intake and Health Study: J of Studies on Alcohol and Drugs | July 2026

Introduction: For decades, low-to-moderate alcohol consumption has been considered by some to offer potential cardiovascular benefits. This comprehensive U.S. modeling study re-evaluated the lifetime health impact of alcohol consumption using contemporary cause-specific data on alcohol-related diseases and injuries. Why was this study needed? Current drinking recommendations remain controversial because many previous studies suggested a protective effect of moderate alcohol intake. Updated evidence was needed to quantify the lifetime risks associated with different drinking levels and patterns. What did the study show? • No overall protective health benefit was observed, even at low levels of alcohol consumption. • Alcohol-related mortality and morbidity increased progressively with increasing weekly alcohol intake. • Lifetime alcohol-attributable mortality exceeded 1 in 1,000 at approximately 7 drinks per week. • At around 8–9 drinks per week, the lifetime risk increased to more than 1 in 100. • Men consuming 14 drinks per week had an estimated 1 in 25 (4%) lifetime risk of dying from an alcohol-attributable cause. • Drinking more than one drink per occasion further increased the risks of breast cancer, cardiovascular disease, and injuries. • The findings support limiting alcohol intake to no more than one standard drink per day for both men and women. Clinical Impact: These findings challenge the long-held perception that moderate alcohol consumption is beneficial. Clinicians should counsel patients that alcohol-related health risks begin at relatively low levels of intake and increase further with higher weekly consumption and binge drinking patterns. Take-Home Message: This large U.S. study found no net health benefit from low-to-moderate alcohol consumption. Alcohol-related health risks rise progressively with increasing intake, supporting a simple public health message: less alcohol is better, and if consumed, intake should ideally be limited to one drink or less per day.

Genetic Testing in Adult Cholestatic Liver Disease: Gut | June 2026

Introduction: Advances in genetic sequencing have transformed the understanding of cholestatic liver diseases. Conditions once considered exclusive to children are now recognized in adolescents and adults, with genetic variants increasingly explaining unexplained cholestasis, recurrent pruritus, and gallstone disease. Why was this review needed? The widespread availability of affordable genetic testing has uncovered pathogenic variants in adults with cholestatic liver disease. Identifying these variants has important implications for diagnosis, prognosis, family screening, and selection of emerging targeted therapies. What did the review show? • Adult cholestatic disorders frequently harbor pathogenic variants in ABCB4, ABCB11, and ATP8B1, the same genes implicated in PFIC. • Genetic cholestasis encompasses a broad spectrum, including PFIC, benign recurrent intrahepatic cholestasis (BRIC), intrahepatic cholestasis of pregnancy (ICP), and low phospholipid-associated cholelithiasis (LPAC). • Genetic testing should be considered in adults with unexplained cholestasis, recurrent cholestatic episodes, severe pruritus, early gallstone disease, or a positive family history. • Identifying the underlying mutation enables more personalized treatment using ursodeoxycholic acid, IBAT inhibitors, or other targeted therapies. • IBAT inhibitors have shown significant benefit in relieving cholestatic pruritus and may have an expanding role beyond pediatric PFIC. • Genetic diagnosis also facilitates genetic counseling, family screening, and improved long-term disease management. Clinical Impact: Genetic evaluation is becoming an essential component of adult cholestatic liver disease rather than a test reserved for rare pediatric disorders. Integrating genomic information into routine hepatology practice enables earlier diagnosis and more individualized therapy. Take-Home Message: Adult cholestatic liver disease is increasingly recognized as a spectrum of inherited disorders. Genetic testing can identify the underlying cause, guide precision treatment, and improve patient outcomes, making genomics an integral part of modern hepatology.

Genetic Testing in Adult Cholestatic Liver Disease: Gut | July 2026

Introduction: Advances in genetic sequencing have transformed the understanding of cholestatic liver diseases. Conditions once considered exclusive to children are now recognized in adolescents and adults, with genetic variants increasingly explaining unexplained cholestasis, recurrent pruritus, and gallstone disease. Why was this review needed? The widespread availability of affordable genetic testing has uncovered pathogenic variants in adults with cholestatic liver disease. Identifying these variants has important implications for diagnosis, prognosis, family screening, and selection of emerging targeted therapies. What did the review show? • Adult cholestatic disorders frequently harbor pathogenic variants in ABCB4, ABCB11, and ATP8B1, the same genes implicated in PFIC. • Genetic cholestasis encompasses a broad spectrum, including PFIC, benign recurrent intrahepatic cholestasis (BRIC), intrahepatic cholestasis of pregnancy (ICP), and low phospholipid-associated cholelithiasis (LPAC). • Genetic testing should be considered in adults with unexplained cholestasis, recurrent cholestatic episodes, severe pruritus, early gallstone disease, or a positive family history. • Identifying the underlying mutation enables more personalized treatment using ursodeoxycholic acid, IBAT inhibitors, or other targeted therapies. • IBAT inhibitors have shown significant benefit in relieving cholestatic pruritus and may have an expanding role beyond pediatric PFIC. • Genetic diagnosis also facilitates genetic counseling, family screening, and improved long-term disease management. Clinical Impact: Genetic evaluation is becoming an essential component of adult cholestatic liver disease rather than a test reserved for rare pediatric disorders. Integrating genomic information into routine hepatology practice enables earlier diagnosis and more individualized therapy. Take-Home Message: Adult cholestatic liver disease is increasingly recognized as a spectrum of inherited disorders. Genetic testing can identify the underlying cause, guide precision treatment, and improve patient outcomes, making genomics an integral part of modern hepatology.

ELF and Liver Disease: Gut | May 2026

Introduction: Early detection of advanced fibrosis in steatotic liver disease remains a major clinical challenge, particularly in individuals with type 2 diabetes and hazardous alcohol use. This real-world UK study evaluated the role of the Enhanced Liver Fibrosis (ELF) test as a community screening tool to identify patients requiring further assessment with liver stiffness measurement (LSM). Why was this study needed? Current liver disease is often diagnosed at an advanced stage when treatment options are limited. Simple, non-invasive screening strategies are needed to identify high-risk individuals earlier and facilitate timely intervention. What did the study show? • Nearly 1,000 high-risk individuals from diabetes and alcohol services underwent ELF testing in routine clinical practice. • Most patients had low ELF scores, avoiding unnecessary referral for further liver assessment. • Patients with diabetes had higher ELF scores than those with hazardous alcohol use. • Among patients undergoing LSM, advanced fibrosis was considerably more common in the alcohol cohort than in the diabetes cohort. • The study highlights that ELF alone may not identify all patients with advanced liver disease, particularly in alcohol-related liver disease. • Combining ELF with liver stiffness measurement improves the detection of clinically significant fibrosis in at-risk populations. Clinical Impact: This study supports the use of the ELF test as an effective first-line, community-based screening tool for patients with diabetes or hazardous alcohol use. However, interpretation should be tailored to the underlying liver disease, and sequential testing with transient elastography may improve diagnostic accuracy. Take-Home Message: The ELF test is a practical non-invasive screening tool for identifying advanced liver disease in high-risk populations. When combined with liver stiffness measurement, it can improve early detection of clinically significant fibrosis and support timely referral for specialist care.

The Liver as a Target for Healthy Aging : Ageing Res Rev | June 2026

Introduction: Aging is a complex biological process that affects multiple organs and progressively increases vulnerability to chronic diseases. Among these organs, the liver occupies a central role in maintaining systemic homeostasis through regulation of glucose and lipid metabolism, nutrient storage, protein synthesis, immune surveillance, and detoxification. Increasing evidence suggests that age-related changes in hepatic function extend beyond the liver itself and may influence the aging trajectory of the entire organism. Problem Statement: While longevity research has traditionally focused on pathways within the nervous, cardiovascular, and musculoskeletal systems, the liver has received comparatively less attention as a therapeutic target for healthy aging. Understanding how liver aging contributes to systemic decline and age-related diseases may reveal novel interventions capable of improving lifespan and healthspan. Summary: This review highlights the liver as a critical regulator of systemic aging and explores how liver-targeted interventions may promote longevity. The authors describe how aging progressively impairs hepatic metabolic flexibility, detoxification capacity, regenerative potential, and immune regulation. These changes increase susceptibility to metabolic dysfunction, chronic inflammation, and tissue injury, which can subsequently influence the function of distant organs through complex interorgan communication networks. The review synthesizes emerging evidence showing that modulation of key hepatic pathways involved in nutrient sensing, mitochondrial function, cellular senescence, oxidative stress, inflammation, and metabolic regulation may slow biological aging. Importantly, many established longevity interventions—including caloric restriction, exercise, and pharmacologic approaches targeting metabolic pathways—appear to exert part of their beneficial effects through actions on the liver. The authors propose that preserving liver health may represent an effective strategy for reducing the burden of age-related diseases, including metabolic disorders, cardiovascular disease, neurodegeneration, and cancer. Beyond its traditional role as a metabolic organ, the liver is increasingly recognized as a central coordinator of whole-body aging processes. This review provides a compelling framework supporting liver-directed therapies as a promising avenue for extending healthspan and promoting healthy aging, while highlighting the need for further translational research to identify clinically applicable liver-targeted longevity interventions.

Bezafibrate Shows Meaningful Long-Term Benefit in PBC : J Hepatol | June 2026

Introduction: Ursodeoxycholic acid (UDCA) remains the first-line treatment for primary biliary cholangitis (PBC), yet a substantial proportion of patients fail to achieve complete biochemical response. Persistent elevation of alkaline phosphatase (ALP) after UDCA therapy is associated with increased risks of liver transplantation and liver-related mortality. Bezafibrate has emerged as an effective adjunctive therapy in patients with incomplete biochemical response, but its clinical benefit has often been reported using relative risk measures that can be difficult to interpret in routine practice. Problem Statement: While previous studies have demonstrated favorable effects of bezafibrate on biochemical markers and long-term outcomes, clinicians require more clinically meaningful measures to understand the magnitude of benefit. The number needed to treat (NNT) provides an intuitive assessment of how many patients need treatment to prevent major clinical events such as transplantation or death. Summary: This study evaluated the projected clinical benefit of bezafibrate in patients with PBC who continued to have elevated ALP levels despite UDCA therapy. Using data from a large national PBC cohort and previously validated treatment-effect estimates, the investigators calculated the number needed to treat to prevent liver transplantation or death. The analysis demonstrated a substantial long-term benefit of bezafibrate, with relatively few patients requiring treatment to prevent one major adverse liver outcome. Importantly, the benefit became more pronounced over longer follow-up periods and was greatest among patients with higher residual ALP levels, reflecting their increased baseline risk. However, clinically meaningful benefits were also observed in patients with only modest ALP elevation after one year of UDCA treatment, suggesting that the therapeutic value of bezafibrate extends beyond traditionally high-risk populations. These findings provide a practical perspective on the magnitude of benefit associated with bezafibrate and strengthen the rationale for its use as an adjunctive therapy in patients with incomplete biochemical response to UDCA. From a clinical standpoint, the results support earlier consideration of bezafibrate in appropriate patients and highlight its potential to reduce progression to liver transplantation and liver-related mo